Presentation TCT 2016 Controversy 5. Adjunctive Pharmacotherapy for TAVR: Real World Usage Patterns of Antiplatelet and Antithrombotic Agents Presenter: Raj Makkar, Lars Sondergaard, Luis Nombela-Franco October 31, 2016
Presentation TCT 2016 TCT 7: Relationship Between Traditional Risk Factors, Platelet Reactivity, and Thrombotic Events: A Mediation Analysis From ADAPT-DES Presenter: Dimitrios Alexopoulos, Laurent Bonello, Bjorn Redfors October 31, 2016
Presentation TCT 2016 TCT 8: Impact of Aspirin Resistance on Outcomes After Coronary Events Presenter: Dimitrios Alexopoulos, Laurent Bonello, Christine Chung October 31, 2016
Presentation TCT 2016 TCT 6: Simultaneous Impact of Thrombotic and Bleeding Risks on Use of Novel P2Y12 Inhibitors in Contemporary PCI: Results From a Large Single-Center Registry Presenter: Dimitrios Alexopoulos, Laurent Bonello, Usman Baber October 31, 2016
Presentation TCT 2016 TCT 5: Risks and Benefits of Dual Antiplatelet Therapy After Coronary Artery Bypass Graft Surgery: Insights From the ACUITY Trial Presenter: Dimitrios Alexopoulos, Laurent Bonello, Ramin Ebrahimi October 31, 2016
News Conference News TCT 2016 ‘Encouraging’ Preliminary Results Seen With Novel, Polymer-Free, Drug-Filled Stent Todd Neale October 31, 2016
Presentation TCT 2016 Debate #2: Is LAA Closure Preferred First-line Treatment in Patients With Recent Stents or ACS? No A Combination of Antiplatelet Agents and Warfarin/NOACs Shoud Be Tried First! Presenter: David R. Holmes Jr., Josep Rodés-Cabau, Freek W.A. Verheugt October 30, 2016
Presentation TCT 2016 Reversal of Chronic Anticoagulation: When, What, and How Effective? Presenter: Paul A. Gurbel, James A. Reiffel October 30, 2016
Presentation TCT 2016 Chronic Oral Anticoagulants: Limitations, Use Recommendations, and Investigational Agents Presenter: Paul A. Gurbel, Christopher B. Granger October 30, 2016
Presentation TCT 2016 Antiplatelet Agents: Limitations, Use Recommendations, and Investigational Agents Presenter: David J. Moliterno October 30, 2016
Presentation TCT 2016 Procedural Anticoagulants: Limitations, Use Recommendations and, Investigational Agents Presenter: Paul A. Gurbel, Harvey D. White October 30, 2016
Presentation TCT 2015 Is There a Role for Oral Anticoagulants After PCI? Presenter: Eric R. Bates, Neal S. Kleiman, C. Michael Gibson October 15, 2015
Presentation TCT 2015 Vorapaxar: Lessons From the Randomized Trials in ACS and for Secondary Prevention Presenter: Eric R. Bates, Neal S. Kleiman, Ori Ben-Yehuda October 15, 2015
Presentation TCT 2015 Should You Bridge in Stented Patients Needing Surgery? Presenter: Eric R. Bates, Neal S. Kleiman, David F. Kong October 15, 2015
News Conference News TCT 2015 Experts Debate Optimal Pharmacologic Approach for STEMI Patients October 11, 2015
News Conference News TCT 2014 Thoughtful Insights at TCT: Uncertainty Surrounds Antithrombotic Therapy in PCI Patients Who Require Anticoagulation Todd Neale October 10, 2014
Presentation TCT 2014 TCT 475: Triple Antithrombotic Therapy Versus Dual Antiplatelet Therapy in Patients with Atrial Fibrillation Undergoing Drug-Eluting Stent Implantation Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Dong Oh Kang September 15, 2014
Presentation TCT 2014 NO: Cangrelor Is No Champion Next to the Appropriate Use of Potent Oral Antiplatelet Agents! Presenter: Dimitrios Alexopoulos September 14, 2014
Presentation TCT 2012 Glycoprotein IIb/IIIa Inhibitors in the Era of Bivalirudin and New Oral Antiplatelet Agents: Is Intracoronary Application the Standard of Choice? Presenter: Rajesh Dave October 25, 2012